The PROSTATE MONITOR test detects a splice variant of the androgen receptor (V7) in the blood. With a frequency of 40-50%, the AR-V7 splice variant appears to be the leading cause of resistance to therapy against the anti-androgenic therapeutics Abiraterone and Lutamides in prostate cancer.
The test is particularly suitable for patients with metastatic prostate carcinoma who are scheduled for anti-androgenic therapy with abiraterone or lutamides or who have been found to have increasing PSA levels among these therapies.
With the detection of the AR-V7 splice variant, your doctor can make an informed treatment decision because your tumor is unlikely to respond to specific anti-androgen drugs.
The PROSTATE MONITOR test shows this variant with a high sensitivity in the blood. The test is cost-effective and can therefore also be used in conjunction with therapy for the early detection of resistance.
The blood sampling is taken in a special tube, which we send after your order to a doctor of your choice. After we have received the blood sample, the result will be available within about two weeks.
Our laboratory is specialized in the above-described analysis. Our state-of-the-art procedures are subject to constant quality control so that we can guarantee you the best possible quality of testing.
How can we help you?
Do you have any questions about our laboratory services, our service and consulting offerings or are you looking for further information? We would like to help you.